GAMMA Investing LLC Raises Stake in LivaNova PLC (NASDAQ:LIVN)

GAMMA Investing LLC raised its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 2,299.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,759 shares of the company’s stock after acquiring an additional 8,394 shares during the period. GAMMA Investing LLC’s holdings in LivaNova were worth $344,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Russell Investments Group Ltd. grew its position in LivaNova by 17.1% during the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock worth $70,000 after acquiring an additional 219 shares during the last quarter. Sterling Capital Management LLC boosted its stake in shares of LivaNova by 800.6% during the fourth quarter. Sterling Capital Management LLC now owns 1,621 shares of the company’s stock valued at $75,000 after purchasing an additional 1,441 shares during the period. Central Pacific Bank Trust Division boosted its stake in shares of LivaNova by 7.0% during the first quarter. Central Pacific Bank Trust Division now owns 4,407 shares of the company’s stock valued at $173,000 after purchasing an additional 290 shares during the period. Vestcor Inc bought a new position in shares of LivaNova in the fourth quarter worth approximately $204,000. Finally, Optimize Financial Inc purchased a new position in shares of LivaNova in the fourth quarter worth $208,000. 97.64% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have weighed in on LIVN. Barclays dropped their price target on shares of LivaNova from $56.00 to $55.00 and set an “equal weight” rating for the company in a research report on Thursday, May 8th. Wolfe Research raised LivaNova from a “peer perform” rating to an “outperform” rating and set a $60.00 target price on the stock in a research note on Tuesday, May 20th. Robert W. Baird boosted their price target on LivaNova from $55.00 to $61.00 and gave the company an “outperform” rating in a report on Thursday, May 8th. Needham & Company LLC reiterated a “buy” rating and issued a $64.00 price objective on shares of LivaNova in a report on Tuesday, May 13th. Finally, Stifel Nicolaus cut their price objective on LivaNova from $72.00 to $60.00 and set a “buy” rating on the stock in a research report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $59.29.

LivaNova Stock Performance

LivaNova stock opened at $45.51 on Friday. LivaNova PLC has a fifty-two week low of $32.48 and a fifty-two week high of $57.35. The stock’s 50 day simple moving average is $41.63 and its two-hundred day simple moving average is $43.67. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.37 and a current ratio of 1.58. The stock has a market cap of $2.48 billion, a price-to-earnings ratio of -11.13 and a beta of 0.90.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.